

**COMMENTARY**

**IMPACT OF *CYP2C9* GENOTYPE ON PHARMACOKINETICS: ARE ALL  
CYCLOOXYGENASE INHIBITORS THE SAME ?**

A. DAVID RODRIGUES

Drug Metabolism and Pharmacokinetics, Bristol-Myers Squibb

Princeton, NJ

**Correspondence Address**

A. David Rodrigues, Ph.D  
Bristol-Myers Squibb,  
Pharmaceutical Research Institute,  
Mailstop F14-04,  
P.O. Box 4000,  
Princeton, NJ 08543  
FAX: (609) 252-7156      TEL: (609) 252-7813  
E-mail: [david.rodrigues@bms.com](mailto:david.rodrigues@bms.com)

**Running title:** Cyclooxygenase inhibitors and cytochrome P450 2C9 genotype

**Abstract:** 215 words

**Introduction:** 1170 words

**Main text:** 5045 words

**Conclusions:** 390 words

**References:** 98

**Number of tables:** 1

<sup>1</sup>**Abbreviations:** P450, cytochrome P450;  $IC_{50(COX)}$ , concentration of inhibitor required to decrease COX activity by 50%;  $AUC_{po(PM)}$ , area under the plasma concentration vs. time curve (oral dose) in subjects phenotyped as PM (expressing one or two variant alleles);  $AUC_{po}$ , area under the plasma concentration vs. time curve (oral dose);  $AUC_{po(EM)}$ , area under the plasma concentration vs. time curve (oral dose) in subjects phenotyped as EM (expressing two wild-type alleles); [S], substrate concentration; PK, pharmacokinetics; PD, pharmacodynamics; PK-PD, pharmacokinetics-pharmacodynamics;  $K_m$ , Michaelis constant;  $V_{max}$ , maximal initial rate of metabolism; COX, cyclooxygenase; NSAIDs, non-steroidal anti-inflammatory drugs;  $f_h$ , fraction of dose eliminated in the liver;  $f_m$ , fraction of total hepatic elimination via all cytochrome P450s;  $f_{m,CYP}$ , fraction of total cytochrome P450 metabolism catalyzed by an individual cytochrome P450 form;  $f_{m,CYP2C9(EM)}$ , fraction of total cytochrome P450 metabolism catalyzed by CYP2C9 in EM (wild type, *CYP2C9\*1/\*1*) subjects; GI, gastrointestinal; CV, cardiovascular; UGT, UDP-glucuronosyltransferase; FMO, flavin-containing monooxygenase; AO, aldehyde oxidase;  $CL_{int}^f$ , intrinsic (metabolite formation) clearance;  $CL_{int,CYP2C9(EM)}^f$ , intrinsic (metabolite formation) clearance catalyzed by CYP2C9 (wild type) in EM subjects;  $CL_{int,CYP2C9(PM)}^f$ , intrinsic (metabolite formation) clearance catalyzed by CYP2C9 (variant forms) in PM subjects; EM, extensive metabolizer phenotype; PM, poor metabolizer phenotype;  $CL_{int}^{tot}$ , total intrinsic clearance (parent consumption); ADME, absorption-distribution-metabolism-excretion; [E], enzyme concentration;  $k_{cat}$ , first order rate constant that relates  $V_{max}$  to [E];  $C_b$ , concentration of COX inhibitor in blood.

## Abstract

The market withdrawals of rofecoxib (Vioxx<sup>®</sup>) and valdecoxib (Bextra<sup>®</sup>) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, *CYP2C9* genotype might be considered a risk factor because many COX inhibitors are *CYP2C9* substrates in vitro. This observation has led some to hypothesize that a reduction in clearance, in subjects expressing variant forms of the enzyme (e.g., *CYP2C9*\*1/\*3 or *CYP2C9*\*3/\*3 genotype), will lead to increased exposure and a greater risk of cardiovascular or gastrointestinal side effects. For any drug, however, one has to consider all clearance pathways. Therefore, a number of COX inhibitors were surveyed and it was determined that *CYP2C9* plays a relatively minor role in the overall clearance ( $\leq 20\%$  of the dose) of sulindac, naproxen, ketoprofen, diclofenac, rofecoxib, and etoricoxib. *CYP2C9* genotype would have no clinically meaningful impact on the pharmacokinetics of these drugs. In contrast, *CYP2C9* genotype is expected to impact the clearance of ibuprofen, indomethacin, flurbiprofen, celecoxib, valdecoxib, lornoxicam, tenoxicam, meloxicam, and piroxicam. However, even when *CYP2C9* is a major determinant of clearance, it is necessary to consider *CYP2C8* genotype (e.g., ibuprofen) and, possibly, *CYP3A4* activity (e.g., celecoxib, valdecoxib, and meloxicam) also.

Events surrounding the market withdrawal of rofecoxib (Vioxx<sup>®</sup>), a potent and selective COX-2<sup>1</sup> inhibitor, have raised concerns about the safety of other COX-2 selective inhibitors such as etoricoxib (Arcoxia<sup>®</sup>), celecoxib (Celebrex<sup>®</sup>), lumiracoxib (Prexige<sup>®</sup>) and valdecoxib (Bextra<sup>®</sup>) (Bing, 2003; Scheen, 2004; Couzin, 2004; Ray et al., 2004; Berenbaum, 2005; Bannwarth, 2005; Fitzgerald, 2004; Mukherjee et al., 2002; Davies and Jamali, 2004; Mukherjee et al., 2002; Kim and Reicin, 2004). Such concerns finally resulted in the withdrawal of valdecoxib about seven months after rofecoxib (Young, 2005; Lenzer, 2005). Non-selective COX inhibitors (NSAIDs) like naproxen, diclofenac, and ibuprofen have also come under scrutiny from regulators, physicians, and patient safety advocacy groups (McGettigan and Henry, 2000; Meagher, 2003).

At the present time, it is thought that the CV and GI side effects of COX inhibitors are related to their mechanism of action. This involves the inhibition of COX, a hemeprotein that exists in two forms (COX-1 and COX-2). COX-1 is expressed constitutively in most tissues, while the expression of COX-2 can be induced by growth factors, cytokines, and vasoactive peptides such as endothelin. In response to cell damage, therefore, COX-2 is inducible by pro-inflammatory mediators and plays a role in the generation of prostaglandin E<sub>2</sub>, a major mediator of inflammatory response. On the other hand, the products of COX-1 are cytoprotective in GI epithelium and selective inhibition of COX-2 is anticipated to reduce inflammation, and modulate pain, without the GI side effects characteristic of non-selective NSAIDs (e.g., peptic erosions, ulceration and bleeding). Consequently, it has become accepted that inhibition of COX-1 should be minimized and the industry has focused on the design of potent and selective COX-2 inhibitors (Justice and Carruthers, 2005; Meagher, 2003; Riendeau, et al., 2001;

Chavez and DeKorte, 2003; Davies et al., 2000; Davies et al., 2003). However, it should be recognized that while COX-2 is inducible, its products are not always pro-inflammatory. Constitutive COX-2 in the vasculature generates mainly prostacyclin, which is a vasodilator and inhibitor of platelet aggregation. Therefore, inhibition of COX-2 may alter the balance of prothrombotic (versus antithrombotic) eicosanoids and predispose susceptible individuals to CV side effects (Justice and Carruthers, 2005; Davies and Jamali, 2004; Meagher, 2003; Mukherjee et al., 2002).

A complex picture is emerging and the clinical safety (both GI and CV) of COX inhibitors most likely depends on a fine balance of factors. These factors include COX-1 and COX-2 inhibitory potency, the  $IC_{50(COX)}$  ratio (COX-2 versus COX-1),  $C_b/IC_{50(COX)}$  ratios, PK, PD, PK-PD (dose response) for each COX form, tissue distribution of the inhibitor (relative to tissue distribution of each COX enzyme form) and therapeutic index (Lees et al., 2004; Meagher et al., 2003; Riendeau et al., 2001; Davies and Jamali, 2004; Justice and Carruthers, 2005). The situation is complicated further by the presence of allelic variant forms of *COX-1* and *COX-2*, which may impact not only efficacy, but predispose individuals to different levels of risk (Halushka et al., 2003; Cipollone et al., 2004).

Factors governing systemic clearance (PK) have received particular attention. This is because the majority of marketed COX inhibitors are well absorbed, metabolized extensively, subject to relatively minimal first pass extraction, and exhibit linear PK ( $[S]/K_m \leq 0.1$ ). Consequently, exposure and  $C_b/IC_{50(COX)}$  ratios will depend on systemic clearance. In turn, systemic clearance will be governed by alterations in  $CL_{int}^{tot}$  in the liver (assuming that  $f_h$  approaches unity). CYP2C9 (CYP2C9\*1) is considered important,

because it has been known for some time that the enzyme plays a role in the metabolism of many NSAIDs in vitro, and is thus considered a major determinant of  $CL_{int}^{tot}$  (Rodrigues and Rushmore, 2002; Miners and Birkett, 1998; Leeman et al., 1993; Zhao et al., 1992). The catalytic efficiency ( $k_{cat}/K_m$  ratio) of the allelic variant forms of the enzyme (e.g., *CYP2C9\*2* and *CYP2C9\*3*) is reduced as a result of a single amino acid substitution (Takanashi et al., 2000; Tang et al., 2001; Miners and Birkett, 1998; Rodrigues and Rushmore, 2002). Therefore, due to the high incidence of *CYP2C9*-related polymorphisms in some populations (e.g., frequency of *CYP2C9\*1/\*3* genotype is 12% in white subjects), one can hypothesize that the occurrence of side effects is increased in numerous subjects genotyped heterozygous, or homozygous, for the *CYP2C9\*2* or *CYP2C9\*3* alleles (Kirchheiner and Brockmoller, 2005; Schwarz, 2003; Lee, 2004; Xie et al., 2002; Rettie and Jones, 2005). However, the picture is not so simple and the data so far are not clear.

For example, Wynne et al (1998) hypothesized that PK might explain the risk of major GI haemorrhage with NSAIDs, with bleeders exhibiting a reduced clearance of NSAIDs compared with non-bleeders. A number of patients (n = 50), hospitalized with GI bleeds while taking piroxicam, indomethacin, diclofenac, or naproxen, were evaluated. There were no significant differences in peak plasma concentration, time-to-peak plasma concentration, or  $AUC_{po}$  between bleeders and controls for any of the NSAIDs studied. The authors concluded that their results failed to support the hypothesis. In a separate study, Martin et al (2001) evaluated the effect of *CYP2C9* genotype on the incidence of gastric ulceration in a relatively small number of subjects (n = 23) receiving indomethacin, diclofenac, naproxen, ibuprofen, piroxicam or sulindac. Although some of

the subjects were genotyped *CYP2C9*\*1/\*2 (17%) and *CYP2C9*\*1/\*3 (13%), the incidence of ulceration was not associated with genotype.

More recently, Martinez et al (2004) were able to assess *CYP2C9* genotyped subjects receiving NSAIDs that underwent “extensive” *CYP2C9*-dependent metabolism (e.g., celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, piroxicam, or naproxen) and other drugs that were not considered *CYP2C9* substrates (e.g., salicylates and acetaminophen). The authors conclude that the association of variant *CYP2C9* alleles and the risk of acute GI bleeding shows a gene-dose effect, and that it is higher in patients receiving drugs that are metabolized mainly by *CYP2C9* (odds ratio of 2.6 when compared to non-bleeding subjects). It is concluded also that *CYP2C9* genotyping may identify a subgroup of individuals who are at a potentially increased risk of acute GI bleeding. Interestingly, the observed risk was related largely to the *CYP2C9*\*2 allele, which is unexpected because decreases in the  $k_{cat}/K_m$  ratio in vitro are more pronounced with recombinant *CYP2C9*\*3 (Rodrigues and Rushmore, 2002). Therefore, the authors hypothesized that the association of *CYP2C9*\*2 with NSAID-related GI bleeding risk may be related to a combined effect of mutations on *CYP2C8* (*CYP2C8*\*3 allele) and *CYP2C9* (*CYP2C9*\*2 allele), and the work of Yasar et al (2002) was cited. This raises an interesting possibility that for substrates metabolized by both *CYP2C8* and *CYP2C9*, an impaired clearance in vivo previously attributed to the *CYP2C9*\*2 variant could in part be related to *CYP2C8*\*3. But how many COX inhibitors are metabolized by *CYP2C9* and *CYP2C8* (Totah and Rettie, 2005) ?

The reports of Wynne et al (1998), Martin et al (2001), and Martinez et al (2004) focused on the GI side effects associated with COX inhibitors. In all three cases,

however, no effort was made to evaluate *CYP2C9* genotype in relation to changes in PK and COX inhibition. More importantly, existing P450 reaction phenotype and clinical ADME data for the drugs in each study were not considered.

### **Kinetic considerations**

Before considering the role of *CYP2C9*, it is important to note that many pathways may contribute to the overall clearance of a drug. For example, an absorbed drug may be cleared unchanged via hepatic (biliary) and renal routes. As a result, not all of the dose is eliminated via hepatic metabolism ( $f_h \cdot f_m \neq 1$ ). Even if a drug is metabolized extensively, it is possible that multiple enzyme systems are involved and the overall clearance is governed by a combination of P450 and non-P450 (e.g., UGT, FMO, or AO) pathways ( $f_m \neq 1$ ). At the same time, even if elimination of drug depends entirely on the P450 system ( $f_m = 1$ ), it is possible that multiple forms of P450 contribute to the overall clearance ( $f_{m,CYP} \neq 1$ ). Under different scenarios, therefore, the product  $f_m \cdot f_{m,CYP}$  does not equal unity ( $CL_{int}^{tot} \neq CL_{int}^f$ ) (Rodrigues and Rushmore, 2002).

For the sake of discussion, the theoretical relationship (Equation 1) between the product  $f_m \cdot f_{m,CYP}$  (specifically,  $f_m \cdot f_{m,CYP2C9(EM)}$ ) and the  $AUC_{po}$  difference in PM ( $AUC_{po(PM)}$ ) versus EM ( $AUC_{po(EM)}$ ) subjects is shown below (Rodrigues and Rushmore, 2002). A similar relationship is commonly used to evaluate the effect of an inhibitor on the AUC of a substrate. In this instance, however, one is comparing the AUC ratio across subjects of different phenotypes, or genotypes, and it is assumed that the dose, the fraction of the dose absorbed, and the unbound fraction in blood is the same in both EM and PM subjects. In addition, it is assumed that gut first pass is negligible, that the drug

is eliminated by the liver only ( $f_h \sim 1$ ), that the elimination process is first order ( $[S]/K_m$  ratio  $\leq 0.1$ ), and that no auto-induction occurs (not relevant following a single dose). One has to accept also that hepatic extraction is blood flow-limited (e.g., well-stirred model). It is worth noting that recombinant CYP2C9\*1 and CYP2C9\*3 have been shown to exhibit non-hyperbolic (non-Michaelis Menten) single- $K_m$  kinetics with substrates such as naproxen (e.g., biphasic) and piroxicam (e.g., substrate inhibition) (Tracy et al., 2002). The impact of such non-hyperbolic kinetics in vivo is not known. However, if product formation (parent elimination) is first order, then concerns about kinetic behavior at higher substrate concentrations ( $\geq K_m$ ) are minimized.

Equation 1:

$$\frac{AUC_{po(PM)}}{AUC_{po(EM)}} = \frac{1}{\left[ \frac{f_m \cdot f_{m,CYP2C9(EM)}}{CL_{int,CYP2C9(EM)}^f / CL_{int,CYP2C9(PM)}^f} \right] + [1 - (f_m \cdot f_{m,CYP2C9(EM)})]}$$

Estimates of  $f_{m,CYP2C9(EM)}$  are based on in vitro P450 reaction phenotyping data, which encompasses inhibition studies with CYP2C9-selective inhibitors like sulfaphenazole or anti-CYP2C9 antibodies. Kinetic studies can be conducted also with human liver microsomes (genotyped tissue) and recombinant P450 proteins (Rodrigues and Rushmore, 2002). At the same time, one can attempt to use clinical ADME data (e.g., fraction of dose recovered in excreta as oxidative metabolites) to generate estimates of  $f_m$ . Again one assumes that the drug is eliminated by the liver only and that non-P450

enzymes, such as FMO and AO, have been ruled out in vitro (Rodrigues and Rushmore, 2002).

EM phenotype ( $AUC_{po(EM)}$  and  $CL_{int,CYP2C9(EM)}^f$ ) is assumed to be associated with *CYP2C9\*1/\*1* genotype. On the other hand, subjects genotyped homozygous (*CYP2C9\*2/\*2* or *CYP2C9\*3/\*3*) or heterozygous (*CYP2C9\*1/\*2* or *CYP2C9\*1/\*3*) for the variant alleles are considered PMs. Overall, the magnitude of the decrease in  $CL_{int}^f$  will be governed by the net effect of variant gene dose, CYP2C9 concentration in the liver ( $[E]$ ), and the effect of the point mutation on  $k_{cat}$  and  $K_m$  ( $CL_{int}^f = V_{max}/K_m = k_{cat} \cdot [E]/K_m$ ). For some drugs, heterozygotes (*CYP2C9\*1/\*2* or *CYP2C9\*1/\*3*) and homozygous wild-type (*CYP2C9\*1/\*1*) subjects will be phenotypically indistinguishable ( $CL_{int,CYP2C9(EM)}^f/CL_{int,CYP2C9(PM)}^f$  ratio  $\sim 1$ ). In this instance, it is only with *CYP2C9\*3/\*3* subjects that one observes higher  $CL_{int,CYP2C9(EM)}^f/CL_{int,CYP2C9(PM)}^f$  ratios ( $> 1$ ).

In reality, therefore, not all COX inhibitors are the same. CYP2C9 may play a relatively minor role in the overall clearance of one drug ( $f_m \cdot f_{m,CYP2C9(EM)} \leq 0.2$ ) and a markedly decreased  $CL_{int}^f$  in PM (*CYP2C9\*3/\*3*) subjects ( $CL_{int,CYP2C9(EM)}^f/CL_{int,CYP2C9(PM)}^f$  ratio  $\sim 10$ ) will lead to relatively modest  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios ( $\leq 1.2$ ) (Rodrigues and Rushmore, 2002). In contrast, CYP2C9 may play a significant role in the overall clearance of a second drug ( $f_m \cdot f_{m,CYP2C9(EM)} > 0.5$ ) and the lower  $CL_{int}^f$  in PM (*CYP2C9\*3/\*3*) subjects results in larger  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios ( $> 2.0$ ).

### Non-selective COX inhibitors

**Sulindac.** Sulindac, a racemic sulfoxide, is pharmacologically inactive and undergoes both reduction to the active sulfide form and oxidation to the inactive sulfone. Once

formed, the sulfide undergoes extensive oxidation back to parent (Hamman et al., 2000; Gibson et al., 1987; Huckler et al., 1973). Formation of the sulfide is catalyzed by AO and does not involve P450 (Kitamura et al., 2001). Similarly, oxidation of the sulfide to the (*R*)-sulfoxide is not catalyzed by P450 and is FMO-dependent in human liver and kidney microsomes (Hamman et al., 2000). Although catalyzed by recombinant human FMOs, the enzymes responsible for (*S*)-sulfoxide formation in tissue microsomes have not been identified (Hamman et al., 2000). However, P450 form-selective inhibitors like sulfaphenazole (CYP2C9 selective) have a minimal impact on (*R*)- and (*S*)-sulfoxide formation in human liver microsomes (Hamman et al., 2000). Therefore, existing data indicate that COX inhibition will be governed by exposure to the sulfide form and the balance of pathways leading to its formation and clearance. CYP2C9 plays a minimal role in both pathways (Table 1).

**Ketoprofen.** At the time of writing, it was not possible to locate any published reports describing the CYP2C9-dependent metabolism of ketoprofen in vitro. However, a number of reports were found that described the clinical ADME profile of the drug. In all cases, it was evident that direct glucuronidation was the major clearance pathway. For example, Jamali and Brocks (1990), Foster et al (1988), and Ishizaki et al (1980) reported that as much as 80% of the dose in man was recovered as the acyl glucuronide. Therefore,  $f_m \bullet f_{m,CYP2C9(EM)}$  is low ( $\leq 0.2$ ) even if the majority of the oxidative metabolism were to be catalyzed by CYP2C9 (Table 1).

**Naproxen.** Like ketoprofen, a large fraction of a naproxen dose (60%) is recovered as the products of direct glucuronidation (Vree et al., 1993a, 1993b). The desmethyl metabolite, formed by P450, more or less accounts for an additional 20% of the dose

recovered in urine. Even if the desmethyl metabolite accounted for all of the dose recovered in bile (~20%), the contribution of P450-dependent oxidation to the overall clearance of naproxen would not exceed 40% of the dose ( $f_m \leq 0.4$ ). Moreover, in vitro reaction phenotyping data indicate that naproxen *O*-demethylation is only partially catalyzed by CYP2C9 ( $\leq 50\%$ ) in human liver microsomes ( $f_{m,CYP2C9(EM)} \leq 0.5$ ). Other P450s such as CYP2C8 and CYP1A2 are involved also (Rodrigues et al., 1996; Miners et al., 1996; Tracy et al., 1997). Therefore, CYP2C9 plays a relatively minor role in the overall clearance of naproxen also ( $f_m \bullet f_{m,CYP2C9(EM)} \leq 0.2$ ) (Table 1).

**Diclofenac.** For naproxen, ketoprofen, and sulindac, there are no reports describing the effect of *CYP2C9* genotype on PK and inhibition of COX activity. The same cannot be said for diclofenac, which was also included in the studies described by Martin et al (2001) and Martinez et al (2004). In fact, a number of labs have reported that the PK of diclofenac is *not* related to *CYP2C9* genotype, despite extensive ( $f_{m,CYP2C9(EM)} \sim 0.8$ ) *CYP2C9*-dependent 4'-hydroxylation in human liver microsomes (Rodrigues and Rushmore, 2002; Brenner et al., 2003; Kirchheiner et al., 2003a). Therefore, one can conclude that *CYP2C9* plays a minor role in the overall clearance of diclofenac ( $f_m \bullet f_{m,CYP2C9(EM)} \leq 0.2$ ) (Table 1). Kirchheiner et al (2003a) showed also that *CYP2C9* genotype has a minimal impact on the inhibition of COX-1 and COX-2 activity in subjects receiving diclofenac. Therefore, a number of groups have questioned the utility of diclofenac as a phenotyping agent (Rodrigues and Rushmore, 2002).

Although human ADME data with genotyped subjects are lacking, Kumar et al (2002) have estimated that the direct glucuronidation of diclofenac to the acyl glucuronide is a more important component to clearance (~75%) than 4'-hydroxylation

( $f_m \sim 0.25$ ). Their findings may explain why *CYP2C9* genotype has a relatively minimal impact on the PK of diclofenac. In addition, the same authors reported that the acyl glucuronide is itself a substrate for *CYP2C8*, which then forms the 4'-hydroxy acyl glucuronide. If corroborated, *CYP2C8* may greatly impact the in vivo estimate of  $CL_{int}^f$  for 4'-hydroxy diclofenac. This estimate is based on the urinary recovery of total 4'-hydroxy diclofenac (conjugated and unconjugated) and is supposedly reflective of *CYP2C9* phenotype. Ultimately, the impact of *CYP2C8* on the disposition of diclofenac and its metabolites will require clinical studies with suitably genotyped subjects.

**Indomethacin.** In the presence of human liver microsomes, indomethacin *O*-demethylation is monophasic (single  $K_m$ ) and is catalyzed largely by *CYP2C9* ( $f_{m,CYP2C9(EM)} \sim 0.9$ ) (Nakajima et al., 1998). However, like naproxen, indomethacin can undergo direct glucuronidation and human ADME data indicate that 22% of the dose is recovered as the acyl glucuronide (Duggan et al., 1972). An additional 11% and 13% of the dose is recovered as unchanged parent drug and *N*-deschlorobenzoylindomethacin. The latter is thought to be formed by carboxylesterase not P450 (Nakajima et al., 1998). Therefore, it can be estimated that about 50% of the dose ( $f_m \sim 0.5$ ) is cleared via P450-dependent metabolism (*O*-demethylation) and that  $f_m \bullet f_{m,CYP2C9(EM)}$  is  $\sim 0.5$  (Table 1). Although there are no published reports of indomethacin pharmacokinetics in genotyped subjects,  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of 1.8 (*CYP2C9*\*3/\*3 versus *CYP2C9*\*1/\*1 subjects) are anticipated. It is not known if such increases in  $AUC_{po}$  will impact the COX-1 and COX-2 inhibition profile of the drug.

**Flurbiprofen.** Data obtained with human liver microsomes and recombinant P450s have shown clearly that the 4'-hydroxylation of flurbiprofen is also monophasic and catalyzed

almost exclusively ( $f_{m,CYP2C9(EM)} > 0.9$ ) by CYP2C9 (Tracy et al., 1995, 1996; Yamazaki et al., 1998). The metabolism and disposition of flurbiprofen has been evaluated in man using radiolabeled and non-radiolabeled drug (Szpunar et al., 1987; Risdall et al., 1978). Some of the dose (23%) is recovered as parent (as free aglycone or acyl glucuronide), with an additional 45% of the dose recovered as 4'-hydroxy flurbiprofen (**M1**). Therefore,  $f_m$  is estimated to be  $\sim 0.5$  and  $f_m \bullet f_{m,CYP2C9(EM)}$  is similar to indomethacin ( $\sim 0.5$ ).

Two additional metabolites of flurbiprofen, 3',4'-dihydroxy flurbiprofen (**M2**) and 3'-hydroxy, 4'-methoxy flurbiprofen (**M3**), each account for up to 5% and 25% of the dose, respectively. Unfortunately, there are no reports describing the sequential metabolism of flurbiprofen, so it is not known if 4'-hydroxy flurbiprofen undergoes further metabolism to **M2** and **M3**. If such sequential metabolism occurs then as much as 75% of the dose ( $f_m \sim 0.75$ ) may be cleared via CYP2C9-dependent 4'-hydroxylation, and estimates of  $f_m \bullet f_{m,CYP2C9(EM)}$  will be as high as 0.75 (Table 1). If true,  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of 3.0 (*CYP2C9\*3/\*3* versus *CYP2C9\*1/\*1* subjects) would be expected. To date, this has not been confirmed clinically and only PK data with heterozygotes (*CYP2C9\*1/\*2* and *CYP2C9\*1/\*3*) have been reported (Lee et al., 2003). In this instance, a statistically significant increase in  $AUC_{po}$  was observed only with *CYP2C9\*1/\*3* subjects (mean  $AUC_{po(PM)}/AUC_{po(EM)}$  ratio = 1.7). Assuming a gene dose effect,  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of greater than 1.7 are possible in *CYP2C9\*3/\*3* subjects. The impact of *CYP2C9* genotype on COX-1 and COX-2 inhibition has not been reported.

**Ibuprofen.** The metabolism of racemic ibuprofen is quite complex (Davies 1998; Rudy et al., 1991). Both (*S*)-(+)-ibuprofen and (*R*)-(-)-ibuprofen are metabolized via acyl glucuronidation, 2-hydroxylation, and 3-hydroxylation (methyl hydroxylation). Once formed, 3-hydroxy ibuprofen is metabolized further to the corresponding carboxy derivative via cytosolic dehydrogenases (Hamman et al., 1997). (*R*)-(-)-ibuprofen undergoes unidirectional chiral inversion, which is significant because pharmacological activity following a racemic dose is attributed largely to the (*S*)-(+)-enantiomer (Davies 1998; Hao et al., 2005).

When incubated with NADPH-fortified human liver microsomes, the oxidative metabolism of racemic ibuprofen is inhibited significantly by sulfaphenazole (87%), which suggests a major role for CYP2C9 (Leemann et al., 1993). This has been supported to some degree by the findings of Hamman et al (1997), who were able to study the metabolism of both enantiomers. For example, the 2- and 3-hydroxylation of the (*S*)-(+)-enantiomer was inhibited (~70%) by sulfaphenazole in human liver microsomes ( $f_{m,CYP2C9(EM)} \sim 0.7$ ). The reaction phenotype data for the (*R*)-(-)-enantiomer were less clear, because the  $k_{cat}/K_m$  ratios (2-hydroxylation) for recombinant CYP2C9 and CYP2C8 were similar. These data have led various groups to conclude that both enzymes catalyze the oxidative metabolism of ibuprofen (Hamman et al., 1997; Hao et al., 2005; Garcia-Martin et al., 2004; Martinez et al., 2005). It is worth noting, however, that CYP2C8-selective chemical inhibitors and immuno-inhibitory antibodies were not available when Hamman et al (1997) conducted their study. Therefore, it is not possible to obtain estimates of  $f_{m,CYP2C9(EM)}$  for the (*R*)-(-)-enantiomer. In reality, more detailed in vitro reaction phenotype data are needed with CYP2C9- and CYP2C8-selective reagents,

recombinant proteins (CYP2C9 and CYP2C8 variants), and a larger number of individual genotyped (*CYP2C9* and *CYP2C8*) human livers. This is important because the ratio of CYP2C9-to-CYP2C8 can vary considerably (1.4 to >300) in different livers (Lasker et al., 1998; Lapple et al., 2003).

Human ADME data indicate that the (*S*)-(+)-enantiomer undergoes no detectable chiral inversion and is cleared via glucuronidation (14% of the dose), 2-hydroxylation (28% of the dose) and carboxy metabolite formation (45% of the dose) (Davies 1998; Rudy et al., 1991). As a result,  $f_m$  is high (~0.7) and *CYP2C9* genotype is expected to impact the PK of (*S*)-(+)-ibuprofen ( $f_m \bullet f_{m,CYP2C9(EM)} \sim 0.5$ ;  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of 1.8 for *CYP2C9*\*3/\*3 versus *CYP2C9*\*1/\*1 subjects) (Table 1). In agreement, Kirchheiner et al (2002) have shown that the AUC of (*S*)-(+)-ibuprofen is increased (1.7-fold) in *CYP2C9*\*3/\*3 subjects (*CYP2C8* genotype not reported) and that the PD relationship describing the inhibition of COX-2 (prostaglandin E<sub>2</sub> formation ex vivo) and COX-1 (thromboxane B<sub>2</sub> formation ex vivo) is altered. It is not know if these alterations in PK-PD make *CYP2C9*\*3/\*3 subjects more susceptible to adverse side effects. More recently, even greater increases (3.0-fold) in (*S*)-(+)-ibuprofen AUC have been reported for *CYP2C9*\*3/\*3 (*CYP2C8*\*1/\*1) subjects (Garcia-Martin et al., 2004). In the same study, the AUC of (*S*)-(+)-ibuprofen was increased as much as 7.7-fold in subjects genotyped *CYP2C9*\*3/\*3 (*CYP2C8*\*1/\*3) or *CYP2C9*\*2/\*2 (*CYP2C8*\*3/\*3). These results suggest that CYP2C8-dependent metabolism of (*S*)-(+)-ibuprofen in vitro may be under-estimated and that the fraction of (*S*)-(+)-ibuprofen clearance via CYP2C8 and CYP2C9 is considerable (>0.8). Such large increases in (*S*)-(+)-ibuprofen AUC will

likely have a major impact on PK-PD following a racemic dose of ibuprofen in a chronic setting.

It has been estimated that as much as 60% of the (*R*)-(-)-ibuprofen dose undergoes chiral inversion to the (*S*)-(+)-enantiomer (Davies 1998). A further 9%, 10%, and 20% of the dose is recovered as the acyl glucuronide, 2-hydroxy, and carboxy metabolites of (*R*)-(-)-ibuprofen, respectively (Davies 1998; Rudy et al., 1991). Therefore, it is estimated that  $f_m$  is low (~0.3) for the (*R*)-(-)-enantiomer ( $AUC_{po(PM)}/AUC_{po(EM)}$  ratio of  $\leq 1.4$  predicted for *CYP2C9*\*3/\*3 versus *CYP2C9*\*1/\*1 subjects). In agreement, Kirchheiner et al (2002) showed that *CYP2C9*\*3/\*3 genotype had a relatively minimal impact on the PK of (*R*)-(-)-enantiomer. In contrast, Garcia-Martin et al (2004) have reported that the AUC of (*R*)-(-)-ibuprofen is increased 2.7-fold in *CYP2C9*\*3/\*3 (*CYP2C8*\*1/\*1) subjects. The difference in the results cannot be explained. In addition, both Martinez et al (2005) and Garcia-Martin et al (2004) have reported that *CYP2C8* genotype does impact the PK of (*R*)-(-)-ibuprofen. For example, (*R*)-(-)-ibuprofen AUC is increased 1.8-fold in *CYP2C8*\*3/\*3 subjects genotyped *CYP2C9*\*1/\*2 or *CYP2C9*\*2/\*2 (Martinez et al., 2005). Larger (~8.0-fold) increases in (*R*)-(-)-ibuprofen AUC are observed in the *CYP2C9*\*3/\*3 (*CYP2C8*\*1/\*3) and *CYP2C9*\*2/\*2 (*CYP2C8*\*3/\*3) subjects described by Garcia-Martin et al (2004). If the results of the latter study are corroborated, this means that the contribution of *CYP2C8* and *CYP2C9* to the overall elimination of (*R*)-(-)-ibuprofen is under-estimated also and contradicts estimates of the fraction of the dose ( $\leq 30\%$ ) cleared via P450 (Davies 1998). The (*R*)-(-)-enantiomer is far less pharmacologically active and the impact of such large increases in AUC is not known.

Overall, it appears that additional clinical data are needed with larger numbers of genotyped subjects.

**Meloxicam.** When meloxicam is incubated with human liver microsomes, 5-hydroxymethyl meloxicam is the major metabolite formed. This metabolite can be oxidized further to 5'-carboxy meloxicam in the presence of hepatocytes or the appropriate subcellular fractions. In human liver microsomes, formation of 5-hydroxymethyl meloxicam is biphasic and the low  $K_m$  (~15  $\mu\text{M}$ ) component is attributed largely to CYP2C9 (Chesne et al., 1998). By comparison, CYP3A4 is a high  $K_m$  P450 (~400  $\mu\text{M}$ ). At a low concentration of meloxicam (10  $\mu\text{M}$ ), methyl hydroxylation is inhibited by sulfaphenazole (80%) and ketoconazole (~20%), which indicates that both P450s are involved ( $f_{m,CYP2C9(EM)}$  ~0.8). Depending on the meloxicam concentration used, and the ratio of CYP3A4-to-CYP2C9 ratio in human liver microsomes, the contribution of CYP3A4 can be as high as 40% ( $f_{m,CYP2C9(EM)}$  ~0.6).

In agreement with in vitro data, the pathway giving rise to 5'-carboxy meloxicam has been identified as major and accounts for about 70% ( $f_m$  ~0.7) of the radiolabeled dose (Schmid et al., 1995). An additional 10% and ~6% of the dose is recovered as parent and ring opened metabolite, respectively. Therefore,  $f_m \bullet f_{m,CYP2C9(EM)}$  is estimated to be 0.4 to 0.6 and  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of 1.6 to 2.2 (*CYP2C9*\*3/\*3 versus *CYP2C9*\*1/\*1 subjects) are anticipated (Table 1). To date, there are no reports describing the effect of *CYP2C9* genotype on the PK of meloxicam.

**Lornoxicam.** Bonnabry et al (1996) and Iida et al (2004) have shown that the 5'-hydroxylation of lornoxicam is catalyzed by CYP2C9 in human liver microsomes ( $f_{m,CYP2C9(EM)}$  > 0.9). Inhibition in the presence of sulfaphenazole (~95%) is very

consistent with the effect of *CYP2C9*\*3/\*3 genotype on the  $V_{\max}/K_m$  ratio (97% decrease). In healthy male volunteers recovery of radioactivity following a single dose of [<sup>14</sup>C]lornoxicam is good (93%) (Hitzenberger et al., 1990; Skjodt and Davies, 1998). Analysis of the urine (~40% of the dose) reveals that 5'-hydroxy lornoxicam is a major metabolite ( $f_m \sim 0.4$ ). This is considered an under-estimate because there are no reports describing radiochromatographic analysis of the feces (~50% of the dose), and it is possible that additional P450 metabolites are present therein. Based on the available data,  $f_m \bullet f_{m,CYP2C9(EM)}$  is estimated to be  $\geq 0.4$  and an  $AUC_{po(PM)}/AUC_{po(EM)}$  ratio of  $\geq 1.6$  (*CYP2C9*\*3/\*3 versus *CYP2C9*\*1/\*1 subjects) is anticipated (Table 1). Recently, it was reported that the  $AUC_{po}$  of lornoxicam is increased 1.9-fold in heterozygous (*CYP2C9*\*1/\*3 or *CYP2C9*\*1/\*2) subjects (Zhang et al., 2005). No *CYP2C9*\*3/\*3 subjects were included in the same study. However, it is reasonable to expect that  $AUC_{po}$  increases will be greater in *CYP2C9*\*3/\*3 subjects.

**Tenoxicam.** Tenoxicam is metabolized extensively (>95%) and about two thirds of the dose is recovered in the urine. The remainder of the dose is eliminated via the bile (Gonzalez and Todd 1987; Nilsen 1994; Dell et al., 1984). 5'-hydroxy tenoxicam (~40% of the dose) and 6-oxy tenoxicam (~30% of the dose) are considered major metabolites (Nilsen 1994). Unfortunately, it is not known if the 6-oxy metabolite is formed by P450 and so estimates of  $f_m$  (~0.4) based on 5'-hydroxy tenoxicam alone are considered tentative. In vitro data show clearly that the 5'-hydroxylation of tenoxicam is catalyzed by *CYP2C9* ( $f_{m,CYP2C9(EM)} \sim 0.8$ ) and that catalytic efficiency is reduced in the presence of recombinant *CYP2C9*\*3 (Takanashi et al., 2000; Zhao et al., 1992). Therefore,  $f_m \bullet f_{m,CYP2C9(EM)}$  is tentatively estimated to be ~0.3 and an  $AUC_{po(PM)}/AUC_{po(EM)}$  ratio ~1.4

(*CYP2C9\*3/\*3* versus *CYP2C9\*1/\*1* subjects) is anticipated (Table 1). If 6-oxy tenoxicam formation is catalyzed by CYP2C9 also, or if the levels of 5'-hydroxy tenoxicam in excreta are under estimated, then  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of  $>1.4$  are expected. This is possible because a 1.8-fold increase in  $AUC_{po}$  has been reported for *CYP2C9\*1/\*3* subjects (Vianna-Jorge et al., 2004). Additional studies are needed in order to evaluate tenoxicam PK in *CYP2C9\*3/\*3* (versus *CYP2C9\*1/\*1*) subjects. In addition, in vitro reaction phenotyping data for 6-oxy tenoxicam are needed. Interestingly, Vianna-Jorge et al (2004) were able to demonstrate a statistically significant increase in tenoxicam  $AUC_{po}$  (1.4-fold) in *CYP2C9\*1/\*2* subjects. To date, however,  $k_{cat}/K_m$  ratios for recombinant CYP2C9\*2 (versus CYP2C9\*1) have not been reported.

**Piroxicam.** Like tenoxicam, piroxicam is metabolized extensively and only a minor fraction of the dose ( $\leq 10\%$ ) is recovered unchanged (Olkola et al., 1994; Woolf and Radulovic, 1989; Richardson et al., 1987; Brogden et al., 1984). Although various metabolites have been identified in human excreta, 5'-hydroxy piroxicam is the major metabolite and accounts for about 60% of the dose ( $f_m \sim 0.6$ ) (Wiseman and Boyle, 1980; Richardson et al., 1987). When incubated with human liver microsomes, 5'-hydroxylation of piroxicam is inhibited by sulfaphenazole ( $\geq 90\%$ ) and so CYP2C9 plays a major role in the reaction ( $f_{m,CYP2C9(EM)} \geq 0.9$ ) (Leemann et al., 1993). In addition, the  $k_{cat}/K_m$  ratio describing 5'-hydroxy piroxicam formation is decreased greatly ( $>90\%$ ) in the presence of recombinant CYP2C9\*3 (Tracy et al., 2002). Therefore,  $f_m \cdot f_{m,CYP2C9(EM)}$  is estimated to be  $\geq 0.54$  and an  $AUC_{po(PM)}/AUC_{po(EM)}$  ratio  $\geq 1.8$  (*CYP2C9\*3/\*3* versus *CYP2C9\*1/\*1* subjects) is anticipated (Table 1). In agreement, piroxicam  $AUC_{po}$  is increased 1.6- and 3.7-fold in *CYP2C9\*1/\*3* and *CYP2C9\*3/\*3* subjects, respectively.

These changes in  $AUC_{po}$  are accompanied by an increase in COX-1 inhibition (56% and 90%, respectively). Like tenoxicam, increases in  $AUC_{po}$  (1.6-fold) are observed also with *CYP2C9\*1/\*2* subjects (J. Perini, Instituto Nacional de Cancer, Universidade Federal do Rio de Janeiro, Brazil, unpublished). At the time of writing, no reports were available describing the  $k_{cat}/K_m$  ratio for recombinant *CYP2C9\*2*.

### **COX-2 selective inhibitors (COX-2/COX-1 $IC_{50}$ ratio $\leq 0.1$ )**

**Rofecoxib.** In vitro data obtained with different subcellular fractions indicate that metabolism of rofecoxib is complex and involves oxidation (5-hydroxylation), hydration, and reduction (Slaughter et al., 2003). The latter two reactions require cytosol, and only the formation of 5-hydroxy rofecoxib in human liver microsomes is catalyzed by P450s (*CYP3A4*, ~60%; *CYP1A2*, ~30%). *CYP2C9* plays a very minor role ( $f_{m,CYP2C9(EM)} < 0.2$ ) in the formation of 5-hydroxy rofecoxib. Following the oral administration of [ $^{14}C$ ]rofecoxib, only a minor fraction of the dose (<1%) is recovered unchanged and as much as 60% is recovered as the various products of reduction (Halpin et al., 2002; Davies et al., 2003). As expected, ketoconazole has a minimal effect on the PK of rofecoxib, despite *CYP3A4* being the most important P450 involved in the formation of 5-hydroxy rofecoxib (Davies et al., 2003). Consequently, P450-dependent metabolism (5-hydroxy rofecoxib  $\gg$  4'-hydroxy rofecoxib and rofecoxib-3',4'-dihydrodiol) cannot account for more than 50% of the dose ( $f_m \leq 0.5$ ) and *CYP2C9* plays a very minor role in the overall clearance of rofecoxib ( $f_m \bullet f_{m,CYP2C9(EM)} \leq 0.1$ ) (Table 1).

**Etoricoxib.** In comparison to rofecoxib, the metabolic profile of etoricoxib is less complex and involves only P450-dependent 6'-methyl hydroxylation and 1'-*N*-oxidation

as primary clearance pathways (Rodrigues et al., 2003; Kassahun et al., 2001). The 6'-methylhydroxy metabolite is major in human liver microsomes and is oxidized further to 6'-carboxy etoricoxib in the presence of cofactor-fortified human liver cytosol. Formation of 6'-hydroxymethyl etoricoxib is catalyzed by CYP3A4 (~60%), with CYP2C9 ( $f_{m,CYP2C9(EM)} < 0.2$ ), CYP2D6, CYP1A2, and CYP2C19 each contributing about 10% (Kassahun et al., 2001). 6'-Carboxy etoricoxib has been identified as the major metabolite following the administration of oral and i.v. [ $^{14}$ C]etoricoxib, and it can be estimated that about 75% of the dose ( $f_m \sim 0.8$ ) is cleared via P450-dependent 6'-methyl hydroxylation (Rodrigues et al., 2003; Kassahun et al., 2001). As in the case of rofecoxib, therefore, CYP2C9 plays a relatively minor role in the overall clearance of etoricoxib ( $f_m \bullet f_{m,CYP2C9(EM)} \leq 0.2$ ) (Table 1).

**Valdecoxib.** Following a single 50-mg oral dose of [ $^{14}$ C]valdecoxib, only a small fraction (~4%) is recovered unchanged (Yuan et al., 2002). About 20% of the recovered dose represents the *N*-glucuronide of parent compound. The products of *N*-hydroxylation, methyl hydroxylation and benzyl hydroxylation, and their various (secondary) metabolites, account for the remainder of the dose (~75%). For valdecoxib, therefore,  $f_m$  is estimated to be ~0.7. Although P450 reaction phenotyping data for valdecoxib have not been published, it has been reported that both CYP2C9 and CYP3A4 metabolize the drug in vitro (Chavez and DeKorte, 2003; Juan et al., 2002). In agreement, fluconazole and ketoconazole increase the  $AUC_{po}$  of valdecoxib 62% and 38%, respectively (Chavez and DeKorte, 2003). Such a result with fluconazole, a known CYP2C9 inhibitor, implies that *CYP2C9* genotype would impact the PK of valdecoxib, although the clinical significance of such an increase in exposure is not known. Prior to withdrawal the drug

was marketed at the 10- and 20-mg dose level, and studies showed good tolerability at 40-mg. Thus it appears that  $AUC_{po}$  increases of less than 2-fold do not require dose adjustment (Chavez and Dekorte, 2003). To date, the impact of *CYP2C9* genotype on valdecoxib PK has not been reported.

**Celecoxib.** There are numerous reports describing the metabolism of celecoxib in vitro. Data indicate that methyl hydroxylation is a major pathway in human liver microsomes, and that the reaction is catalyzed largely (70% to 90%) by *CYP2C9* ( $f_{m,CYP2C9(EM)} \geq 0.7$ ) with *CYP3A4* playing less of a role ( $\leq 25\%$ ) (Tang et al., 2000; Sandberg et al., 2002). The results of additional studies show that the contribution of *CYP2C9* (versus *CYP3A4*) in a bank of human liver microsomes is greatly dependent on the *CYP3A4*-to-*CYP2C9* content ratio (Tang et al., 2001). The contribution of *CYP2C9* is greater ( $f_{m,CYP2C9(EM)} \sim 0.8$ ) in livers where *CYP3A4* levels are lower. When the *CYP3A4*-to-*CYP2C9* content ratio is high ( $\sim 8.0$ ), the contribution of *CYP3A4* increases to 40% ( $f_{m,CYP2C9(EM)} \sim 0.6$ ).

There are two reports describing the metabolism of celecoxib after incubation with human liver microsomes of genotyped subjects and preparations of recombinant *CYP2C9* (Tang et al., 2001; Sandberg et al., 2002). In both cases, it was shown that the reduction in catalytic efficiency was greater for recombinant *CYP2C9*\*3 ( $\geq 70\%$ ) than *CYP2C9*\*2 ( $\leq 35\%$ ). The report of Sandberg et al., (2002) included livers from a larger set of organ donors and it was demonstrated that the rate of celecoxib hydroxylation was decreased ( $\sim 50\%$ ) in livers genotyped *CYP2C9*\*1/\*3 (versus *CYP2C9*\*1/\*1). In contrast, celecoxib hydroxylation was impacted minimally in livers genotyped *CYP2C9*\*1/\*2. The same study also included one liver genotyped *CYP2C9*\*3/\*3 ( $\sim 80\%$  decrease in activity) and four livers genotyped *CYP2C9*\*2/\*2 (36% decrease in activity).

Once formed, methyl hydroxy celecoxib is oxidized further to the corresponding carboxylic acid metabolite via cytosolic alcohol dehydrogenase. Therefore, the metabolic profile of celecoxib is relatively simple (Sandberg et al., 2002). This is borne out in human subjects receiving a single oral dose of [<sup>14</sup>C]celecoxib, where the overall recovery of the dose is good (~95%) (Paulson et al., 2000). In such subjects, up to 86% of the dose is recovered as methyl hydroxy celecoxib and carboxy celecoxib ( $f_m \sim 0.9$ ). CYP2C9, therefore, is predicted to play a major role in the overall clearance of celecoxib ( $f_m \bullet f_{m,CYP2C9(EM)} = 0.5-0.8$ ) and  $AUC_{po(PM)}/AUC_{po(EM)}$  ratios of 1.8 to 3.6 (CYP2C9\*3/\*3 versus CYP2C9\*1/\*1 subjects) are anticipated (Table 1).

At the time of writing, three reports described the PK of celecoxib in adult (CYP2C9 genotyped) subjects. Two reported PK for a single dose of celecoxib (Kirchheiner et al., 2003b; Tang et al., 2001), while the third described steady state PK parameters following twice daily doses of celecoxib (200-mg) for 15 days (Brenner et al., 2003). It is clear from all three reports that CYP2C9\*1/\*2 genotype has a minimal impact on celecoxib PK. In agreement with Brenner et al (2003), Kirchheiner et al (2003b) showed that the  $AUC_{po}$  of celecoxib in CYP2C9\*2/\*2 subjects is not statistically different from those individuals genotyped CYP2C9\*1/\*1. In all three studies, the  $AUC_{po}$  in CYP2C9\*1/\*3 subjects was ~2.0-fold higher (versus CYP2C9\*1/\*1 subjects). However, it is important to note that such an increased  $AUC_{po}$  was observed in only two out of the four CYP2C9\*1/\*3 subjects included in the study conducted by Brenner et al (2003). Interestingly, one CYP2C9\*3/\*3 individual was included in the same study and no difference in  $AUC_{po}$  (vs. CYP2C9\*1/\*1) was observed. This does not agree with the observations of Tang et al (2001) and Kirchheiner et al (2003b), who reported a 2.2-fold

(n = 1 subject) and 3.3-fold (n = 3 subjects) higher  $AUC_{po}$  in their respective *CYP2C9*\*3/\*3 subjects. The results of Brenner et al (2003) are also difficult to reconcile in light of the fact that the  $AUC_{po}$  of single dose celecoxib is increased (~2.3-fold) following fluconazole (Davies et al., 2000). More recently, Stempak et al (2005) reported that the  $AUC_{po}$  of a single celecoxib dose (250-mg/m<sup>2</sup> dose, equivalent to 400-mg) was ~10-fold higher in a pediatric patient genotyped *CYP2C9*\*3/\*3 (versus two *CYP2C9*\*1/\*1 patients). A similar result was obtained at a steady state following a bid regimen at the same dose level.

Although ketoconazole has no effect on the  $AUC_{po}$  of celecoxib (Davies et al., 2000), it is possible that higher CYP3A4 activity may have compensated and negated the impact of *CYP2C9*\*3/\*3 genotype in some of the individuals reported by Brenner et al (2003). Alternatively, it is possible that, upon multiple dosing (e.g., 200 mg bid), celecoxib might behave as an auto-inducer of CYP3A4 and CYP2C9 in *CYP2C9*\*3/\*3 subjects (maximal plasma concentrations of total celecoxib at steady state are projected to be close to 15  $\mu$ M in these subjects). At least in vitro, celecoxib (1 to 15  $\mu$ M) has been shown to transactivate human pregnane-X-receptor and induce CYP3A4 in immortalized human hepatocytes (Fa2N-4 cells) (Michael Sinz, Bristol-Myers Squibb, personal communication). Therefore, induction of CYP3A4 in the gut and liver during celecoxib first pass is a possibility.

Additional studies are needed and it will be necessary to evaluate the effect of *CYP2C9* genotype and CYP3A4 activity on celecoxib PK, and COX inhibition, following multiple doses of the drug. This is important because dose adjustment has been recommended for subjects receiving fluconazole and other CYP2C9 inhibitors

(<http://www.fda.gov/cder/foi/label/2005/020998s0171b1.pdf>). Unfortunately, in the absence of widespread *CYP2C9* genotyping, it will not be possible to adjust the dose of celecoxib prospectively.

**Lumiracoxib.** It has been reported that lumiracoxib is “extensively” metabolized by *CYP2C9* in vitro, although the in vitro metabolic profile and P450 reaction phenotype have not been published (Mangold et al., 2004). Despite metabolism by *CYP2C9* in vitro, fluconazole has a relatively minimal effect on the PK of lumiracoxib (~1.2-fold increase in  $AUC_{po(EM)}$ ) and its ability to inhibit COX-1. Although additional “compensatory” metabolic pathways have been proposed, such pathways are not apparent (Scott et al., 2004; Mangold et al., 2004). For example, only a minor fraction of a [ $^{14}C$ ]lumiracoxib dose (<10%) is recovered unchanged, or in the form of lumiracoxib acyl glucuronide. In fact, the majority of the dose in *CYP2C9*\*1/\*1 subjects is recovered as the products of oxidation on the 5-methyl group and dihaloaromatic ring (Mangold et al., 2004). Despite the minimal effect of fluconazole, the impact of *CYP2C9* genotype on lumiracoxib PK needs to be determined.

## Conclusions

If it is assumed that the CV and GI side effects of COX inhibitors are related to systemic exposure, then factors governing their clearance will be considered important. Because most COX inhibitors (NSAIDs) are metabolized by *CYP2C9* in vitro, *CYP2C9* genotype may be considered by some to be a clinically relevant risk factor. The variant forms of *CYP2C9* (e.g., *CYP2C9*\*3) are less catalytically efficient and one could hypothesize that systemic exposure, and the risk of side effects, is elevated in subjects

expressing one or more variant alleles. In addition, variant allele frequency is high in Caucasian populations (~15%) and some may advocate the widespread genotyping of patients receiving COX inhibitors. Regrettably, the reports of Wynne et al (1998), Martin et al (2001), and Martinez et al (2004), and the survey presented herein, illustrate the complexity of the situation. It is estimated that *CYP2C9* genotype is irrelevant for nearly half of the sixteen COX inhibitors surveyed. This includes at least two of the COX-2 selective inhibitors described (rofecoxib and etoricoxib), three of the six drugs reported by Martin et al (2001), and two of the seven “extensive” *CYP2C9* substrates reported by Martinez et al (2004). When it comes to *CYP2C9* genotype, and its impact on PK, it is clear that not all COX inhibitors are the same.

Even when *CYP2C9* involvement is major, one has to critically evaluate each COX inhibitor on an individual basis, and take into account the available data related to *all* clearance mechanisms (e.g., renal clearance, direct conjugation, non-P450 oxidation, and metabolism by other P450s). This is important for currently marketed COX inhibitors such as ibuprofen and celecoxib, where additional P450 forms have been implicated in clearance and literature reports appear contradictory (Kirchheiner et al., 2002; Garcia-Martin et al., 2004; Brenner et al., 2003; Kirchheiner et al., 2003b). Other considerations, such as the size of the clinical dataset and the dosing regimen, are important also. Most of the clinical examples cited herein describe studies with limited numbers of genotyped subjects receiving a single dose of drug. Therefore, additional studies employing larger numbers of genotyped (*COX*, *CYP2C9* and *CYP2C8*) and phenotyped (*CYP2C9*, *CYP2C8* and *CYP3A4*) patients on chronic therapy are warranted.

It is only with long-term study of such patients that one can assess critically the impact of *CYP2C9* genotype on PK, PD, *and* the side effect profile.

## References

Bannwarth B (2005) Do selective cyclo-oxygenase-2 inhibitors have a future? *Drug Saf* **28**:183-189.

Berenbaum F (2005) VIOXX and cardiovascular events: a class effect? *Joint Bone Spine* **72**:1-3.

Bing RJ (2003) Cyclooxygenase-2 inhibitors: is there an association with coronary or renal events? *Curr Atheroscler Rep* **5**:114-117.

Brenner SS, Herrlinger C, Dilger K, Murdter TE, Hofmann U, Marx C and Klotz U (2003) Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. *Clin Pharmacokinet* **42**: 283-292.

Bonnabry P, Leemann T and Dayer P (1996) Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam. *Eur J Clin Pharmacol* **49**:305-308.

Brogden RN, Heel RC, Speight TM and Avery GS (1984) Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. *Drugs* **28**:292-323.

Chavez ML and DeKorte CJ (2003) Valdecoxib: a review. *Clin Ther* **25**: 817-851.

Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E and Sauter T (1998) Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. *Xenobiotica* **28**:1-13.

Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cucurullo C, Pini B, Ursi S, Vitullo G, Averna M, Arca M, Montali A, Campagna F, Uchino S, Spigonardo F, Taddei S, Viridis A, Ciabattini G, Notarbartolo A, Cucurullo F and Mezzetti A (2004) Identification of New Elements of Plaque Stability (INES) Study Group. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. *J Amer Med Assoc* **291**: 2221-2228.

Couzin J (2004) Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. *Science* **306**:384-385.

Davies NM (1998) Clinical pharmacokinetics of ibuprofen. The first 30 years. *Clin Pharmacokinet* **34**:101-154.

Davies NM, McLachlan AJ, Day RO and Williams KM (2000) Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. *Clin Pharmacokinet* **38**: 225-242.

Davies NM, Teng XW and Skjodt NM (2003) Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. *Clin Pharmacokinet* **42**: 545-556.

Davies NM and Jamali F (2004) COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. *J Pharm Pharmaceut Sci* **7**:332-336.

Dell D, Joly R, Meister W, Arnold W, Partos C and Guldemann B (1984) Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine. *J Chromatogr* **317**: 483-492.

Duggan DE, Hogans AF, Kwan KC and McMahon FG (1972) The metabolism of indomethacin in man. *J Pharmacol Exp Ther* **181**:563-575.

Fitzgerald GA (2004) Coxibs and cardiovascular disease. *N Engl J Med* **35**:1709-1711.

Foster RT, Jamali F, Russell AS and Alballa SR (1988) Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses. *J Pharm Sci* **77**:70-73.

Garcia-Martin E, Martinez C, Tabares B, Frias J and Agundez JA (2004) Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. *Clin Pharmacol Ther* **76**:119-127.

Gibson TP, Dobrinska MR, Lin JH, Entwistle LA and Davies RO (1987) Biotransformation of sulindac in end-stage renal disease. *Clin Pharmacol Ther* **42**:82-88.

Gonzalez JP and Todd PA (1987) Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. *Drugs* **34**:289-310.

Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP and Baillie TA (2002) The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. *Drug Metab Dispos* **30**: 684-693.

Halushka MK, Walker LP and Halushka PV (2003) Genetic variation in cyclooxygenase 1: effects on response to aspirin. *Clin Pharmacol Ther* **73**:122-130.

Hamman MA, Thompson GA and Hall SD (1997) Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochem Pharmacol* **54**:33-41.

Hamman MA, Haehner-Daniels BD, Wrighton SA, Rettie AE and Hall SD (2000) Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes. *Biochem Pharmacol* **60**:7-17.

Hao H, Wang G and Sun J (2005) Enantioselective pharmacokinetics of ibuprofen and involved mechanisms. *Drug Metab Rev* **37**: 215-234.

Hitzenberger G, Radhofer-Welte S, Takacs F and Rosenow D (1990) Pharmacokinetics of lornoxicam in man. *Postgrad Med J* **66 (Suppl 4)**:S22-S27.

Hucker HB, Stauffer SC, White SD, Rhodes RE, Arison BH, Umbenhauer ER, Bower RJ and McMahon FG (1973) Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. *Drug Metab Dispos* **1**:721-736.

Iida I, Miyata A, Arai M, Hirota M, Akimoto M, Higuchi S, Kobayashi K and Chiba K (2004) Catalytic roles of CYP2C9 and its variants (CYP2C9\*2 and CYP2C9\*3) in lornoxicam 5'-hydroxylation. *Drug Metab Dispos* **32**:7-9.

Ishizaki T, Sasaki T, Suganuma T, Horai Y, Chiba K, Watanabe M, Asuke W and Hoshi H (1980) Pharmacokinetics of ketoprofen following single oral, intramuscular and rectal doses and after repeated oral administration. *Eur J Clin Pharmacol* **18**: 407-414.

Jamali F and Brocks DR (1990) Clinical pharmacokinetics of ketoprofen and its enantiomers. *Clin Pharmacokinet* **19**:197-217.

Justice E and Carruthers DM (2005) Cardiovascular risk and COX-2 inhibition in rheumatological practice. *J Hum Hypertens* **19**:1-5.

Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N and Rodrigues AD (2001) Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. *Drug Metab Dispos* **29**:813-820.

Kim PS and Reicin AS (2004) Rofecoxib, Merck, and the FDA. *N Engl J Med* **351**:2875-2878.

Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I and Brockmoller J (2002) Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. *Clin Pharmacol Ther* **72**: 62-75.

Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I and Brockmoller J (2003a) Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. *Br J Clin Pharmacol* **55**: 51-61.

Kirchheiner J, Stormer E, Meisel C, Steinbach N, Roots I and Brockmoller J (2003b) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. *Pharmacogenetics* **13**:473-480.

Kirchheiner J and Brockmoller J (2005) Clinical consequences of cytochrome P450 2C9 polymorphisms. *Clin Pharmacol Ther* **77**:1-16.

Kitamura S, Ohashi KNK, Sugihara K, Hosokawa R, Akagawa Y and Ohta S (2001) Extremely high drug-reductase activity based on aldehyde oxidase in monkey liver. *Biol Pharm Bull* **24**:856-859.

Kumar S, Samuel K, Subramanian R, Braun MP, Stearns RA, Chiu SH, Evans DC and Baillie TA (2002) Extrapolation of diclofenac clearance from in vitro microsomal metabolism data: role of acyl glucuronidation and sequential oxidative metabolism of the acyl glucuronide. *J Pharmacol Exp Ther* **303**: 969-978.

Lapelle F, von Richter O, Fromm MF, Richter T, Thon KP, Wisser H, Griese EU, Eichelbaum M and Kivisto KT (2003) Differential expression and function of CYP2C isoforms in human intestine and liver. *Pharmacogenetics* **13**:565-575.

Lasker JM, Wester MR, Aramsombatdee E and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. *Arch Biochem Biophys* **353**:16-28.

Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA and Goldstein JA (2003) Differences in flurbiprofen pharmacokinetics between CYP2C9\*1/\*1, \*1/\*2, and \*1/\*3 genotypes. *Eur J Clin Pharmacol* **58**:791-794.

Lee CR (2004) CYP2C9 genotype as a predictor of drug disposition in humans.

*Methods Find Exp Clin Pharmacol* **26**: 463-472.

Leemann TD, Transon C, Bonnabry P and Dayer P (1993) A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs.

*Drugs Exp Clin Res* **19**:189-195.

Lees P, Giraudel J, Landoni MF and Toutain PL (2004) PK-PD integration and PK-PD modelling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. *J Vet Pharmacol Ther* **27**: 491-502.

Lenzer J (2005) Pfizer is asked to suspend sales of painkiller.

*Brit Med J* **330**: 862.

Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J and Rordorf C (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. *Drug Metab Dispos* **32**: 566-571.

Martin JH, Begg EJ, Kennedy MA, Roberts R and Barclay ML (2001) Is cytochrome P450 2C9 genotype associated with NSAID gastric ulceration? *Br J Clin Pharmacol* **51**: 627-630.

Martinez C, Blanco G, Ladero JM, Garcia-Martin E, Taxonera C, Gamito FG, Diaz-Rubio M and Agundez JA (2004) Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. *Br J Pharmacol* **141**: 205-208.

Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM and Agundez JA (2005) The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (*R*)-ibuprofen enantiomer in healthy subjects. *Br J Clin Pharmacol* **59**:62-69.

McGettigan P and Henry D (2000) Current problems with non-specific COX inhibitors. *Curr Pharm Des* **6**:1693-1724.

Meagher EA (2003) Balancing gastroprotection and cardioprotection with selective cyclo-oxygenase-2 inhibitors: clinical implications. *Drug Saf* **26**:913-924.

Miners JO, Coulter S, Tukey RH, Veronese ME and Birkett DJ (1996) Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic *O*-demethylation of *R*- and *S*-naproxen. *Biochem Pharmacol* **51**:1003-1008.

Miners JO and Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. *Br J Clin Pharmacol* **45**: 525-538.

Mukherjee D, Nissen SE, and Topol EJ (2002) Risk of cardiovascular events associated with selective COX-2 inhibitors. *J Amer Med Assoc* **286**:954-959.

Nakajima M, Inoue T, Shimada N, Tokudome S, Yamamoto T and Kuroiwa Y (1998) Cytochrome P450 2C9 catalyzes indomethacin *O*-demethylation in human liver microsomes. *Drug Metab Dispos* **26**: 261-266.

Nilsen OG (1994) Clinical pharmacokinetics of tenoxicam. *Clin Pharmacokinet* **26**:16-43.

Olkkola KT, Brunetto AV and Mattila MJ (1994) Pharmacokinetics of oxycam nonsteroidal anti-inflammatory agents. *Clin Pharmacokinet* **26**:107-120.

Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH Jr, Piergies A and Karim A (2000) Metabolism and excretion of [<sup>14</sup>C]celecoxib in healthy male volunteers. *Drug Metab Dispos* **28**:308-314.

Ray WA, Griffin MR and Stein CM (2004) Cardiovascular toxicity of valdecoxib. *N Engl J Med* **351**: 2767.

Rettie AE and Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. *Annu Rev Pharmacol Toxicol* **45**:477-494.

Richardson CJ, Blocka KL, Ross SG and Verbeeck RK (1987) Piroxicam and 5'-hydroxypiroxicam kinetics following multiple dose administration of piroxicam. *Eur J Clin Pharmacol* **32**: 89-91.

Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falguyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN and Chan CC (2001). Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. *J Pharmacol Exp Ther* **296**:558-566.

Risdall PC, Adams SS, Crampton EL and Marchant B (1978) The disposition and metabolism of flurbiprofen in several species including man. *Xenobiotica* **8**: 691-703.

Rodrigues AD, Kukulka MJ, Roberts EM, Ouellet D and Rodgers TR (1996) [*O*-methyl <sup>14</sup>C]naproxen *O*-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. *Drug Metab Dispos* **24**: 126-136.

Rodrigues AD and Rushmore TH (2002) Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. *Curr Drug Metab* **3**: 289-309.

Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC and Agrawal NG (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. *Drug Metab Dispos* **31**: 224-232.

Rudy AC, Knight PM, Brater DC and Hall SD (1991) Stereoselective metabolism of ibuprofen in humans: administration of *R*-, *S*- and racemic ibuprofen. *J Pharmacol Exp Ther* **259**:1133-1139.

Sandberg M, Yasar U, Stromberg P, Hoog JO and Eliasson E (2002) Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. *Br J Clin Pharmacol* **54**: 423-429.

Scheen AJ (2004) Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs? *Rev Med Liege* **59**:565-569.

Schwarz UI (2003) Clinical relevance of genetic polymorphisms in the human CYP2C9 gene. *Eur J Clin Invest* **33 (Suppl 2)**:23-30.

Schmid J, Busch U, Heinzl G, Bozler G, Kaschke S and Kummer M (1995) Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. *Drug Metab Dispos* **23**:1206-1213.

Scott G, Yih L, Yeh CM, Milosavljev S, Laurent A and Rordorf C (2004) Lumiracoxib: pharmacokinetic and pharmacodynamic profile when coadministered with fluconazole in healthy subjects. *J Clin Pharmacol* **44**:193-199.

Skjodt NM and Davies NM (1998) Clinical pharmacokinetics of lornoxicam. *Clin Pharmacokin* **34**: 421-428.

Slaughter D, Takenaga N, Lu P, Assang C, Walsh DJ, Arison BH, Cui D, Halpin RA, Geer LA, Vyas KP and Baillie TA (2003) Metabolism of rofecoxib in vitro using human liver subcellular fractions. *Drug Metab Dispos* **31**:1398-1408.

Stempak D, Bukaveckas BL, Linder M, Koren G and Burachel S (2005) CYP2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. *Clin Pharmacol Ther*, on line.

Szpunar GJ, Albert KS, Bole GG, Dreyfus JN, Lockwood GF and Wagner JG (1987) Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. *Biopharm Drug Dispos* **8**: 273-283.

Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M and Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. *Pharmacogenetics* **10**:95-104.

Tang C, Shou M, Mei Q, Rushmore TH and Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. *J Pharmacol Exp Ther* **293**: 453-459.

Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI and Rodrigues AD (2001) In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. *Pharmacogenetics* **11**:223-235.

Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ and Korzekwa KR (1995) Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (*R*)- and (*S*)-flurbiprofen. *Biochem Pharmacol* **49**:1269-1275.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ and Korzekwa KR (1996) Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. *Biochem Pharmacol* **52**:1305-1309.

Tracy TS, Marra C, Wrighton SA, Gonzalez FJ and Korzekwa KR (1997) Involvement of multiple cytochrome P450 isoforms in naproxen *O*-demethylation. *Eur J Clin Pharmacol* **52**: 293-298.

Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA and Dickmann LJ (2002) Polymorphic variants (CYP2C9\*3 and CYP2C9\*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. *Drug Metab Dispos* **30**:385-390.

Total RA and Rettie AE (2005) Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. *Clin Pharmacol Ther* **77**: 341-352.

Vianna-Jorge R, Perini JA, Rondinelli E and Suarez-Kurtz G (2004) CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians. *Clin Pharmacol Ther* **76**:18-26.

Vree TB, van den Biggelaar-Martea M, Verwey-van Wissen CP, Vree JB and Guelen PJ (1993a) Pharmacokinetics of naproxen, its metabolite *O*-desmethylnaproxen, and their acyl glucuronides in humans. *Biopharm Drug Dispos* **14**:491-502.

Vree TB, Van Den Biggelaar-Martea M, Verwey-Van Wissen CP, Vree ML and Guelen PJ (1993b) The pharmacokinetics of naproxen, its metabolite *O*-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. *Br J Clin Pharmacol* **35**:467-472.

Wiseman EH and Boyle JA (1980) Piroxicam. *Clinics in Rheumatic Diseases* **6**: 585-613.

Woolf TF and Radulovic LL (1989) Oxicams: metabolic disposition in man and animals. *Drug Metab Rev* **21**: 255-276.

Wynne HA, Long A, Nicholson E, Ward A and Keir D (1998) Are altered pharmacokinetics of non-steroidal anti-inflammatory drugs (NSAIDs) a risk factor for gastrointestinal bleeding? *Br J Clin Pharmacol* **4**:405-408.

Xie HG, Prasad HC, Kim RB and Stein CM (2002) CYP2C9 allelic variants: ethnic distribution and functional significance. *Adv Drug Deliv Rev* **54**:1257-1270.

Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP and Shimada T (1998) Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. *Biochem Pharmacol* **56**:243-251.

Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U and Rane A (2002) Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. *Biochem Biophys Res Commun* **299**:25-28.

Young D (2005) FDA ponders future of NSAIDs: Pfizer reluctantly withdraws Bextra. *Am J Health Syst Pharm* **62**: 997-1000.

Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A and Findlay JW (2002) Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. *Drug Metab Dispos* **30**:1013-1021.

Zhang Y, Zhong D, Si D, Guo Y, Chen X and Zhou H (2005) Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype. *Br J Clin Pharmacol* **59**:14-17.

Zhao J, Leemann T and Dayer P (1992) In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. *Life Sci* **51**:575-581.

**Table 1***Metabolism of various COX inhibitors by CYP2C9<sup>a</sup>*

COX Inhibitor	$f_m$	$f_{m,CYP2C9(EM)}$	$f_m \bullet f_{m,CYP2C9(EM)}$	Effect of <i>CYP2C9</i> genotype on PK ?	Effect of fluconazole on $AUC_{po}$ (fold-increase)	$AUC_{po(PM)}/AUC_{po(EM)}$ <sup>b</sup>
<i>Non-selective COX inhibitors</i>						
Sulindac <sup>c</sup>	<0.1	<0.1	<0.1	- <sup>i</sup>	-	<1.1
Naproxen	≤0.4	≤0.5	≤0.2	-	-	≤1.2
Ketoprofen	~0.2	-	≤0.2	-	-	≤1.2
Diclofenac	<0.3	0.8	≤0.2	Minimal effect	<1.2	≤1.2
Indomethacin	0.5	0.9	0.5	-	-	1.8
Flurbiprofen	0.5-0.8 <sup>d</sup>	>0.9	0.5-0.8	Yes	-	1.8-3.6
( <i>S</i> )-Ibuprofen	0.7	0.7	0.5	Yes	-	1.8
( <i>R</i> )-Ibuprofen	0.3 <sup>f</sup>	-	-	Yes	-	-
Piroxicam	~0.6	≥0.9	≥0.5	Yes	-	≥1.8
Lornoxicam	≥0.4	>0.9	≥0.4	Yes	-	≥1.6
Tenoxicam	~0.4 <sup>h</sup>	~0.8	~0.3	Yes	-	~1.4
Meloxicam	0.7	0.6-0.8 <sup>g</sup>	0.4-0.6	-	-	1.6-2.2

**Table 1 (Continued)**

COX Inhibitor	$f_m$	$f_{m,CYP2C9(EM)}$	$f_m \bullet f_{m,CYP2C9(EM)}$	Effect of <i>CYP2C9</i> genotype on PK ?	Effect of fluconazole on $AUC_{po}$ (fold-increase)	$AUC_{po(PM)}/AUC_{po(EM)}$ <sup>b</sup>
<i>COX-2 selective inhibitors (COX-2/COX-1 IC<sub>50</sub> ratio <math>\leq 0.1</math>)<sup>e</sup></i>						
Rofecoxib	$\leq 0.5$	$< 0.2$	$\leq 0.1$	-	-	$\leq 1.1$
Etoricoxib	$\sim 0.8$	$< 0.2$	$\leq 0.2$	-	-	$\leq 1.2$
Lumiracoxib	$> 0.7$	-	-	-	$\sim 1.2$	-
Valdecoxib	$\sim 0.7$	-	-	-	1.6	-
Celecoxib	$\sim 0.9$	0.6-0.9 <sup>g</sup>	0.5-0.8	Yes	2.3	1.8-3.6

### Legend to Table 1

<sup>a</sup>The various factors governing the contribution of CYP2C9 to the overall clearance of each COX inhibitor are considered:  $f_m$ , fraction of total hepatic elimination due to all cytochrome P450s;  $f_{m,CYP2C9(EM)}$ , fraction of total cytochrome P450 metabolism catalyzed by CYP2C9 in EM (wild type, *CYP2C9\*1/\*1*) subjects;  $f_m \bullet f_{m,CYP2C9(EM)}$ , product of  $f_m$  and  $f_{m,CYP2C9(EM)}$ . Values for each parameter are obtained from the references cited in the text. The effect of fluconazole and *CYP2C9* genotype on the PK ( $AUC_{po}$ ) of some of the COX inhibitors has been reported (references cited in the text).

<sup>b</sup>Anticipated ratio of  $AUC_{po}$  in PM (*CYP2C9\*3/\*3*) versus EM (*CYP2C9\*1/\*1*) subjects assuming that the  $CL_{int,CYP2C9(EM)}^f / CL_{int,CYP2C9(PM)}^f$  ratio is ~10 (i.e., 90% decrease in  $CL_{int}^f$ ) (Equation 1).

<sup>c</sup>Data refer to the pharmacologically active sulfide metabolite of sulindac.

<sup>d</sup>Assumes metabolism of flurbiprofen to 4'-hydroxy flurbiprofen, and the further (sequential) metabolism of 4'-hydroxy flurbiprofen to 3',4'-dihydroxy flurbiprofen and 3'-hydroxy, 4'-methoxy flurbiprofen.

<sup>e</sup>Ratio of  $IC_{50}$  values for COX-2 and COX-1 in vitro using human whole blood (Riendeau et al., 2001).

<sup>f</sup>Assumes that 60% and ~10% of the (*R*)-(-)-ibuprofen dose undergoes unidirectional chiral inversion and direct glucuronidation, respectively.

<sup>g</sup>CYP3A4 is involved in metabolism and its contribution varies depending on expression levels. Therefore,  $f_{m,CYP2C9(EM)}$  varies depending on the CYP3A4-to-CYP2C9 concentration ratio in different livers.

<sup>h</sup>Only the 5'-hydroxylation of tenoxicam is considered, because it is not known if P450 is involved in 6-oxy tenoxicam formation.

<sup>i</sup>Data not reported in the literature, or data are available but additional studies are needed.